Monitoring of Piperacillin-Tazobactam and Meropenem Plasmatic Levels in Critical Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-02-15

Study Completion Date

2021-03-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to establish the Piperacillin-Tazobactam and Meropenem Plasmatic Levels to know if it´s necessary to make some adjustment in the recommended dose regimen.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Piperacillin/Tazobactam in Critically Ill Patients With Severe Sepsis and Septic Shock

NCT02730624

Early Phase of Severe Sepsis and Septic Shock

COMPLETED PHASE4

PK/PD of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock

NCT02820987

Septic Shock

COMPLETED PHASE3

Observed Pharmacokinetic of Piperacillin/Tazobactam Compared to Amikacin in ICU

NCT03990467

Septic Shock Sepsis Sepsis Syndrome

UNKNOWN NA

Piperacillin Pharmacokinetics in ICU Patients

NCT02478073

Sepsis Septic Shock

UNKNOWN

Piperacillin PK Analysis in Severe Sepsis Patients

NCT02569086

Sepsis Severe Sepsis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis Septic Shock

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Piperacillin-Tazobactam or Meropenem Cohort

Patients hospitalized for sepsis or septic shock that are treated with Piperacillin-Tazobactam or Meropenem and meet all the inclusion criteria and none of the exclusion criteria.

Piperacillin/tazobactam or Meropenem

Intervention Type DRUG

The plasmatic levels determinations will always be made in state of equilibrium (after the fourth dose) and two samples will be collected:

1. Just before the antibiotic infusion (T0)
2. In the midpoint of time (T50). If the antibiotic is administered every 8 hours this determination will be made at 4 hours. If the antibiotic is administered every 6 hours, the determination will be made at 3 hours.

A second complete determination will be made (before the infusion, in the midpoint of time and before the next dose) after the administration of 4 doses as long as a posology modification is made as a consequence of the information received from the plasmatic levels.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Piperacillin/tazobactam or Meropenem

The plasmatic levels determinations will always be made in state of equilibrium (after the fourth dose) and two samples will be collected:

1. Just before the antibiotic infusion (T0)
2. In the midpoint of time (T50). If the antibiotic is administered every 8 hours this determination will be made at 4 hours. If the antibiotic is administered every 6 hours, the determination will be made at 3 hours.

A second complete determination will be made (before the infusion, in the midpoint of time and before the next dose) after the administration of 4 doses as long as a posology modification is made as a consequence of the information received from the plasmatic levels.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients above 18 years old.
* Hospitalized in the Intense Care Unit.
* Patients treated with Piperacillin-Tazobactam or Meropenem.
* Septic shock.
* Renal hyper clearance.
* Gram-negative bacillary bacteremia.
* Continuous renal replacement technique.
* ECMO.
* Obesity (BMI\> 40).